Pain Therapeutics (NASDAQ: PTIE) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Pain Therapeutics to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, dividends, earnings and institutional ownership.
Earnings & Valuation
This table compares Pain Therapeutics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pain Therapeutics||N/A||-$14.85 million||-2.26|
|Pain Therapeutics Competitors||$284.28 million||$34.29 million||82.58|
This is a breakdown of recent recommendations and price targets for Pain Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pain Therapeutics Competitors||857||3201||11603||231||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.17%. Given Pain Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Pain Therapeutics has less favorable growth aspects than its rivals.
Volatility & Risk
Pain Therapeutics has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Pain Therapeutics’ rivals have a beta of 5.90, meaning that their average stock price is 490% more volatile than the S&P 500.
Institutional and Insider Ownership
36.2% of Pain Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 32.7% of Pain Therapeutics shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Pain Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pain Therapeutics Competitors||-5,311.45%||-218.34%||-39.53%|
Pain Therapeutics rivals beat Pain Therapeutics on 9 of the 12 factors compared.
About Pain Therapeutics
Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company’s drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.
What are top analysts saying about Pain Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pain Therapeutics Inc. and related companies.